Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CURASIGHT Aktie jetzt für 0€ handeln | |||||
Do | CURASIGHT: Half-year report Q2 2025 | 1 | Cision News | ||
Di | Curasight receives approval for brain cancer treatment trial | 1 | Investing.com | ||
Di | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT in brain cancer patients | 176 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform.Initiation of the study marks a key... ► Artikel lesen | |
23.06. | Curasight A/S announces outcome of T03 warrant exercise | 2 | Cision News | ||
18.06. | Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT in brain cancer patients | 1 | Cision News | ||
13.06. | Spotlight Stock Market: Market Notice 110/25 - Last day of trading in Curasight A/S's subscription option CURAS TO 3 | 1 | Cision News | ||
03.06. | CURASIGHT: The exercise period commences for warrants of series TO3 on 4 June 2025 | 1 | Cision News | ||
02.06. | Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue | 1 | Cision News | ||
28.05. | CURASIGHT: Completed registration of rights issue | 1 | Cision News | ||
28.05. | Resolutions of the Annual General Meeting 2025 of Curasight A/S | 1 | Cision News | ||
21.05. | Curasight announces outcome in rights issue | 1 | Cision News | ||
15.05. | Subscription of new shares in the Right Issue 2025 exercised by Curasight management | 1 | Cision News | ||
13.05. | CURASIGHT: Notice of Annual General Meeting 2025 | 1 | Cision News | ||
13.05. | Last day of the subscription period in Curasight's rights issue of shares | 2 | Cision News | ||
07.05. | Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer | 2 | Cision News | ||
06.05. | Curasight's rights issue subscription period has commenced | 2 | Cision News | ||
02.05. | THE SUBSCRIPTION PERIOD IN CURASIGHT'S RIGHTS ISSUE OF SHARES BEGINS TODAY | 2 | Cision News | ||
30.04. | Curasight to present at HC Andersen Capital | 2 | Cision News | ||
29.04. | Curasight A/S publishes disclosure document regarding rights issue | 2 | Cision News | ||
28.04. | Spotlight Stock Market: Market Notice 73/25 - Information regarding the rights issue from Curasight A/S | 2 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,710 | +0,16 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 58,58 | +0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
BIONTECH | 85,65 | +0,06 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
IMMUNOVANT | 14,690 | -0,88 % | Immunovant, Inc. - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 11,610 | -9,72 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
EVOTEC | 6,000 | +0,03 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
LENZ THERAPEUTICS | 38,630 | +1,13 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,710 | -2,91 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
AVIDITY BIOSCIENCES | 46,540 | -4,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
ARRIVENT BIOPHARMA | 19,120 | -0,52 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
RAPPORT THERAPEUTICS | 17,630 | +4,94 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS)... ► Artikel lesen | |
CRISPR THERAPEUTICS | 44,200 | -0,45 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
RECURSION PHARMACEUTICALS | 4,690 | -3,60 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
ADMA BIOLOGICS | 17,255 | -0,72 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
DYNE THERAPEUTICS | 13,480 | -1,96 % | Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy |